Biosimilars are entering the U.S. market, and, no matter what role a company plays in the healthcare landscape, biosimilars will be a disrupter.
The key challenge companies need to face now is how they will adapt their commercial strategies to be successful. The biosimilars market will continue to evolve rapidly and with uncertainty. No matter their strategic objectives, all biopharmaceutical companies in the ecosystem need to be ever-present and stay in tune with the pulse of this disruptive and rapidly evolving market.
KPMG provides strategic counsel to brand-name and biosimilars companies across Europe and now in the U.S. Our focus is on helping biopharmaceutical companies make effective product choices, optimize their product launches, and balance their product mix.
© 2021 KPMG Central Services, a Belgian Economic Interest Grouping ("ESV/GIE") and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.
For more detail about the structure of the KPMG global organization please visit https://home.kpmg/governance.